Anthem Biosciences Limited files SEBI Takeover Regulations disclosure
Anthem Biosciences, a listed pharmaceutical company, has submitted a Regulation 31 disclosure to NSE under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Regulation 31(4) and 31(5) require disclosure by the acquirer within 2 working days of acquisition/crossing a slab of shares. The filing does not yet disclose the acquirer's identity, shareholding %, or offer price in the headline; these are detailed in the form DIS-4 appended to the NSE announcement.
Why it mattersFiling under Reg 31(4)–31(5) indicates acquisition of ≥5% stake (or crossing a slab threshold), obligating disclosure within 2 working days and potentially triggering open offer obligations if acquirer breaches 25% threshold; counsel must confirm whether acquirer is obliged to launch a mandatory offer.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Disclosure Filing (NSE Archives) · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026